Amoéba Unanimously positive EU vote on active substance as biocontrol
Amoéba received unanimous positive votes from all 27 EU Member States for its active substance to be used as a low-risk biocontrol. The vote followed a positive scientific opinion from EFSA in January 2025 and now paves the way for the European Commission to formalize the approval through an implementing regulation. The vote supports Amoéba's plans to commercialize its biocontrol product Axpera, with first EU sales expected by late 2025 or 2026, as the final product is already undergoing regulatory review across several EU countries. We expect the launch to be focussed initially on grapes and high-value vegetables across countries in Western and Mediterranean Europe. Meanwhile, Amoéba is also finalizing its partnership with Koppert. We reiterate a Buy rating and € 1.7 TP.Amoeba SA. Amoeba SA is a France-based company that develops, manufactures and markets biological products. The Company specializes in disruptive biological solutions for the treatment of Legionella, amoeba and biofilm in water. The Company's offering includes products and services, such as: Cleantech biological solution, a patented technological disruptive product with no impact on the environment; amoebic analyses of waters of wet cooling towers (TAR), hot sanitary waters, industrial waters and waters of swimming pools; as well as Legionella tests of industrial waste water, among others. The Company is engaged in various technical, commercial, industrial and investment partnerships.
We are a financial services provider for several types of professional clients, each with distinct needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.